Chronic inflammatory demyelinating polyradiculoneuropathy
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
History and exam
Key diagnostic factors
common
disease progression
Most patients have either a chronic progressive course or a relapsing-remitting course over >8 weeks.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
Rarely, patients present with subacute onset over 4-8 weeks with a monophasic course.[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [7]Oh SJ, Kurokawa K, de Almeida DF, et al. Subacute inflammatory demyelinating neuropathy. Neurology. 2003 Dec 9;61(11):1507-12. http://www.ncbi.nlm.nih.gov/pubmed/14663033?tool=bestpractice.com [8]Nevo Y, Pestronk A, Kornberg AJ, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996 Jul;47(1):98-102. http://www.ncbi.nlm.nih.gov/pubmed/8710133?tool=bestpractice.com This presentation is more common in children.[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [9]Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve. 1997 Aug;20(8):1008-15. http://www.ncbi.nlm.nih.gov/pubmed/9236792?tool=bestpractice.com
weakness
Over 90% of patients report weakness that is typically symmetrical, involves all four limbs, and affects proximal and distal muscles.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com [4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
Rarely, weakness affects arms more than legs or is asymmetrical.[12]Lewis RA, Sumner AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982 Sep;32(9):958-64. http://www.ncbi.nlm.nih.gov/pubmed/7202168?tool=bestpractice.com [14]Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating polyneuropathy. Brain. 1996 Jun;119 (Pt 3):765-74. https://academic.oup.com/brain/article/119/3/765/396265 http://www.ncbi.nlm.nih.gov/pubmed/8673489?tool=bestpractice.com [67]Gorson KC, Ropper AH, Weinberg DH. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 1999 Jun;22(6):758-65. http://www.ncbi.nlm.nih.gov/pubmed/10366230?tool=bestpractice.com
Pure motor syndromes occur rarely.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83. https://onlinelibrary.wiley.com/doi/10.1111/ene.14959 http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com [68]Kimura A, Sakurai T, Koumura A, et al. Motor-dominant chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010 Apr;257(4):621-9. http://www.ncbi.nlm.nih.gov/pubmed/20361294?tool=bestpractice.com [69]Pegat A, Boisseau W, Maisonobe T, et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treatment. J Peripher Nerv Syst. 2020 Jun;25(2):162-70. http://www.ncbi.nlm.nih.gov/pubmed/32364302?tool=bestpractice.com
Distal CIDP (also known as distal acquired demyelinating symmetrical neuropathy) presents with predominant distal weakness.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83. https://onlinelibrary.wiley.com/doi/10.1111/ene.14959 http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com [10]Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol. 2003 Feb;60(2):260-4. https://jamanetwork.com/journals/jamaneurology/fullarticle/783675 http://www.ncbi.nlm.nih.gov/pubmed/12580713?tool=bestpractice.com
altered sensation
Numbness or paraesthesia is noted in about 75% of patients.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com [4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com The prevalence of pain due to CIDP at any time during the disease course was estimated as 46% in one systematic review.[37]Michaelides A, Hadden RDM, Sarrigiannis PG, et al. Pain in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Pain Ther. 2019 Dec;8(2):177-85. https://link.springer.com/article/10.1007/s40122-019-0128-y http://www.ncbi.nlm.nih.gov/pubmed/31201680?tool=bestpractice.com
Nearly all patients have symmetrical distal sensory loss to large- and small-fibre modalities.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com [4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
Rarely, patients present with only sensory symptoms, typically distal paraesthesias and dysaesthesias.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83. https://onlinelibrary.wiley.com/doi/10.1111/ene.14959 http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com [38]Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):677-80. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489203/pdf/jnnpsyc00493-0043.pdf http://www.ncbi.nlm.nih.gov/pubmed/1326601?tool=bestpractice.com [39]Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve. 2013 Nov;48(5):727-32. http://www.ncbi.nlm.nih.gov/pubmed/23424105?tool=bestpractice.com
Pure sensory syndromes occur in <10% of patients and may be either mixed large- and small-fibre or predominantly large-fibre, in which sensory ataxia is the major manifestation.[38]Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):677-80. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489203/pdf/jnnpsyc00493-0043.pdf http://www.ncbi.nlm.nih.gov/pubmed/1326601?tool=bestpractice.com [39]Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve. 2013 Nov;48(5):727-32. http://www.ncbi.nlm.nih.gov/pubmed/23424105?tool=bestpractice.com [70]Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997 Feb;48(2):321-8. http://www.ncbi.nlm.nih.gov/pubmed/9040714?tool=bestpractice.com [71]Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999 Feb;52(3):498-503. http://www.ncbi.nlm.nih.gov/pubmed/10025777?tool=bestpractice.com In pure sensory syndromes, nerve conduction studies may show only mild abnormalities not meeting typical electrodiagnostic criteria. Elevated cerebrospinal fluid protein, abnormal somatosensory evoked potentials, and demyelination on nerve biopsy may be present.[38]Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):677-80. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC489203/pdf/jnnpsyc00493-0043.pdf http://www.ncbi.nlm.nih.gov/pubmed/1326601?tool=bestpractice.com [39]Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve. 2013 Nov;48(5):727-32. http://www.ncbi.nlm.nih.gov/pubmed/23424105?tool=bestpractice.com
decreased deep tendon reflexes
Hyporeflexia or areflexia is a required component in most sets of diagnostic criteria and occurs in >90% of patients.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93. https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com [4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
Other diagnostic factors
common
incoordination
Gait difficulty is usually due to weakness. However, presentation with a sensory ataxia is also described rarely in patients.[70]Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997 Feb;48(2):321-8. http://www.ncbi.nlm.nih.gov/pubmed/9040714?tool=bestpractice.com [71]Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999 Feb;52(3):498-503. http://www.ncbi.nlm.nih.gov/pubmed/10025777?tool=bestpractice.com
age 40 to 60 years
Can occur at any age (although rare in childhood), but the most common age of onset is between 40 and 60 years.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83. https://onlinelibrary.wiley.com/doi/10.1111/ene.14959 http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
uncommon
preceding infection
Because of the chronic nature of the disease, it can be difficult to document a temporal relationship, but most studies suggest that 10% to 30% of patients have a preceding infection.[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com [17]Rajabally YA, Peric S, Bozovic I, et al. Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: a European collaborative study. Muscle Nerve. 2021 Dec;64(6):657-61. http://www.ncbi.nlm.nih.gov/pubmed/34263956?tool=bestpractice.com
absence of exposure to neuropathy-causing drugs
Drug or toxin exposure that is likely to have caused the neuropathy (e.g., diphtheria, buckthorn, amiodarone, tacrolimus) may rule out a diagnosis of CIDP.[32]London Z, Albers JW. Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin. 2007 Feb;25(1):257-76. http://www.ncbi.nlm.nih.gov/pubmed/17324727?tool=bestpractice.com [33]Herskovitz S, Schaumberg HH. Neuropathy caused by drugs. In: Dyck PJ, Thomas PK, eds. Peripheral neuropathy. Philadelphia, PA: Elsevier Saunders; 2005:2553-83.
dyspnoea
Shortness of breath requiring intubation occurs in <5% of patients.[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [70]Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997 Feb;48(2):321-8. http://www.ncbi.nlm.nih.gov/pubmed/9040714?tool=bestpractice.com [72]Henderson RD, Sandroni P, Wijdicks EF. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol. 2005 Oct;252(10):1235-7. http://www.ncbi.nlm.nih.gov/pubmed/15940387?tool=bestpractice.com
facial weakness
Occurs in about 15% of patients.[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
dysarthria
Occurs in about 15% of patients.[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
dysphagia
Occurs in about 15% of patients.[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30. http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com [5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63. http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com [6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
urinary incontinence
Occurs in about 25% of patients and is often mild.[73]Stamboulis E, Katsaros N, Koutsis G, et al. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2006 Jan;33(1):78-84. https://onlinelibrary.wiley.com/doi/10.1002/mus.20438 http://www.ncbi.nlm.nih.gov/pubmed/16184605?tool=bestpractice.com [74]Lyu RK, Tang LM, Wu YR, et al. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002 Nov;26(5):669-72. http://www.ncbi.nlm.nih.gov/pubmed/12402289?tool=bestpractice.com
urinary urgency or hesitancy
Occurs in about 25% of patients and is often mild.[73]Stamboulis E, Katsaros N, Koutsis G, et al. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2006 Jan;33(1):78-84. https://onlinelibrary.wiley.com/doi/10.1002/mus.20438 http://www.ncbi.nlm.nih.gov/pubmed/16184605?tool=bestpractice.com [74]Lyu RK, Tang LM, Wu YR, et al. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002 Nov;26(5):669-72. http://www.ncbi.nlm.nih.gov/pubmed/12402289?tool=bestpractice.com
impotence
Occurs in about 25% of patients.[73]Stamboulis E, Katsaros N, Koutsis G, et al. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2006 Jan;33(1):78-84. https://onlinelibrary.wiley.com/doi/10.1002/mus.20438 http://www.ncbi.nlm.nih.gov/pubmed/16184605?tool=bestpractice.com [74]Lyu RK, Tang LM, Wu YR, et al. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002 Nov;26(5):669-72. http://www.ncbi.nlm.nih.gov/pubmed/12402289?tool=bestpractice.com
orthostatic hypotension
Occurs in about 25% of patients.[73]Stamboulis E, Katsaros N, Koutsis G, et al. Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2006 Jan;33(1):78-84. https://onlinelibrary.wiley.com/doi/10.1002/mus.20438 http://www.ncbi.nlm.nih.gov/pubmed/16184605?tool=bestpractice.com [74]Lyu RK, Tang LM, Wu YR, et al. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002 Nov;26(5):669-72. http://www.ncbi.nlm.nih.gov/pubmed/12402289?tool=bestpractice.com
papilloedema
May be present but is usually mild.[75]Thomas PK, Walker RW, Rudge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain. 1987 Feb;110 (Pt 1):53-76. http://www.ncbi.nlm.nih.gov/pubmed/3026554?tool=bestpractice.com [76]Mendell JR, Kolkin S, Kissel JT, et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1987 Aug;37(8):1291-4. http://www.ncbi.nlm.nih.gov/pubmed/3614649?tool=bestpractice.com [77]Falcone M, Scalise A, Minisci C, et al. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Neurol Sci. 2006 Apr;27(1):58-62. http://www.ncbi.nlm.nih.gov/pubmed/16688601?tool=bestpractice.com
vision loss
May be present but is usually mild.[75]Thomas PK, Walker RW, Rudge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain. 1987 Feb;110 (Pt 1):53-76. http://www.ncbi.nlm.nih.gov/pubmed/3026554?tool=bestpractice.com [76]Mendell JR, Kolkin S, Kissel JT, et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1987 Aug;37(8):1291-4. http://www.ncbi.nlm.nih.gov/pubmed/3614649?tool=bestpractice.com [77]Falcone M, Scalise A, Minisci C, et al. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Neurol Sci. 2006 Apr;27(1):58-62. http://www.ncbi.nlm.nih.gov/pubmed/16688601?tool=bestpractice.com
spasticity
May be present but is usually mild.[75]Thomas PK, Walker RW, Rudge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain. 1987 Feb;110 (Pt 1):53-76. http://www.ncbi.nlm.nih.gov/pubmed/3026554?tool=bestpractice.com [76]Mendell JR, Kolkin S, Kissel JT, et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1987 Aug;37(8):1291-4. http://www.ncbi.nlm.nih.gov/pubmed/3614649?tool=bestpractice.com [77]Falcone M, Scalise A, Minisci C, et al. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Neurol Sci. 2006 Apr;27(1):58-62. http://www.ncbi.nlm.nih.gov/pubmed/16688601?tool=bestpractice.com
Risk factors
weak
male sex
CIDP is more common in men than in women, with reported male-to-female ratios of between 1.4 and 4.4.[15]Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3-4):161-72. https://karger.com/ned/article/52/3-4/161/226983/Incidence-and-Prevalence-of-Chronic-Inflammatory http://www.ncbi.nlm.nih.gov/pubmed/30669140?tool=bestpractice.com
autoimmune diseases
May co-exist with other autoimmune diseases, such as systemic lupus erythematosus, connective tissue disease, inflammatory bowel disease, thyroid disease, sarcoidosis, glomerulonephritis, chronic active hepatitis, or graft-versus-host disease.[19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142. https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com [20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9. https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com
diabetes mellitus
There is an increased incidence of CIDP in patients with diabetes mellitus, and severity of CIDP may be worse in these patients.[18]Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016 Sep-Oct;30(7):1401-7. https://www.sciencedirect.com/science/article/pii/S1056872716301349 http://www.ncbi.nlm.nih.gov/pubmed/27389526?tool=bestpractice.com [19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142. https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com [20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9. https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com
infection
Can occur in association with infection, including HIV.[19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142. https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com [20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9. https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com
monoclonal gammopathy of undetermined significance (MGUS)
About 10% to 15% of patients have a benign MGUS, most often with an IgA or IgG paraprotein; MGUS may affect disease course and response to treatment.[2]Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019 Aug;18(8):784-94. http://www.ncbi.nlm.nih.gov/pubmed/31076244?tool=bestpractice.com [19]Chen Y, Tang X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases: identification and management. Front Immunol. 2022 Jul 4;13:890142. https://www.frontiersin.org/articles/10.3389/fimmu.2022.890142/full http://www.ncbi.nlm.nih.gov/pubmed/35860284?tool=bestpractice.com [20]Doneddu PE, Cocito D, Manganelli F, et al; Italian CIDP Database study group. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1092-9. https://air.unimi.it/retrieve/dfa8b9a4-ea52-748b-e053-3a05fe0a3a96/Manuscript%20JNNP%20Diabetes%20Final.pdf http://www.ncbi.nlm.nih.gov/pubmed/32868387?tool=bestpractice.com
Use of this content is subject to our disclaimer